Morse Asset Management’s Ascendis Pharma A/S ASND Stock Holding History

Morse Asset Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.56M	Buy	9,589 +562	+6%	+$131K	0.42%	57
2026 Q1	$2.06M	Buy	9,027 +2,538	+39%	+$569K	0.43%	60
2025 Q4	$1.38M	Buy	+6,489	New	+$1.34M	0.28%	78

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Morse Asset Management's ASND Position: Q2 2026 in Review

Morse Asset Management increased its Ascendis Pharma A/S (ASND) stake by 6.2% in Q2 2026, buying an estimated $131K and bringing the position to 9,589 shares worth $2.56M. The position accounts for 0.42% of the portfolio, ranked #57.

Morse Asset Management first reported a position in ASND in Q4 2025 and has held it in 3 quarters since. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Morse Asset Management held 9,589 shares of Ascendis Pharma A/S worth $2.56M as of Q2 2026.
Morse Asset Management bought 562 Ascendis Pharma A/S shares in Q2 2026, an estimated $131K.
Ascendis Pharma A/S made up 0.42% of Morse Asset Management's portfolio in Q2 2026, its #57 holding.
Morse Asset Management first reported a position in Ascendis Pharma A/S in Q4 2025 and has held it in 3 quarters since.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Morse Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.